PALO ALTO, Calif.  , July 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing, and commercializing transformative therapeutics, announced today it will host an investor R&D Day webcast on Wednesday, July 16, 2025, from 4:00 pm ET to 5:30 pm ET.

The virtual event will feature a comprehensive overview of Kodiak's three late-phase clinical assets (tarcocimab, KSI-501, KSI-101) through presentations from members of Kodiak's senior leadership team complemented by distinguished industry experts.

A live webcast of this event will be available to investors and other interested parties.

Registration for the event is available here: https://edge.media-server.com/mmc/p/crrqmwef, as well as on the "Events and Presentations" section of Kodiak's website at https://ir.kodiak.com.

A recording of the webcast and presentation can be viewed as early as 24 hours after the event.

Kodiak Sciences Inc.

Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform^® uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's maturing pipeline includes three late-phase clinical assets, all three targeting Phase 3 topline data in 2026.

For more information, please visit www.kodiak.com. 

Kodiak^®, Kodiak Sciences^®, ABC^®, ABC Platform^®, ABCD™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding Kodiak's plans, commitments, aspirations and goals related to Kodiak's drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled "Risk Factors" in Kodiak's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC") as well as discussions of potential risks, uncertainties, and other important factors in Kodiak's subsequent filings with the SEC. All information in this press release is as of the date presented, and Kodiak undertakes no duty to update such information unless required by law.